leisure time -WSS

leisure time

author：hotspot 2025-09-27 16:22:34 - browse：7173

Photograph of an abandoned lab with empty bottle, boxes, and beakers all around. -- biotech coverage from STAT — Adobe

SAN DIEGO — It was spring 2020, and Histogen, a small biotech with big ambitions to regenerate tissues throughout the body and turn a profit in the process, had just gone public. The company’s leadership believed they were poised for success — until everything slowly and irreversibly fell apart.

Three years later, Histogen no longer develops therapies. It has abandoned efforts to reverse baldness, replenish cartilage in achy knees, and quell infection and inflammation.

The company has no lab. It has no headquarters. It has just two employees, including a chief financial officer who also serves as secretary, CEO, and president. Histogen’s stock trades below $1 a share. And even that is coming to a close. On Thursday, the Nasdaq suspended trading of Histogen shares after determining that the company’s operations and assets are negligible, meaning the biotech is now officially a shell of its former self.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

explore

leisure time

WSS

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Readout LOUD podcast: A CRISPR milestone, biotech mixology

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Lasker Awards 2023: Winners in biomedical research

Medical student insurance fails on mental health care coverage

Biotech lab space demand falls sharply

knowledge

leisure time

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout LOUD podcast: A CRISPR milestone, biotech mixology

The cancer drug shortage isn’t new — and neither are the solutions

It's been 20 years since Dolly the sheep. Where's my clone?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

In key trial, Verve's treatment lowers cholesterol levels in patients

Walensky prepares to leave CDC — and Congress — behind

Gain of function research would be limited under House proposal

Bright Health sells Medicare Advantage business to Molina

How Vertex's cystic fibrosis drug is changing patients' lives

explore

CDC's new outbreak response network to include Northeastern

U.K. considers world's first use of meningitis vaccine to address gonorrhea

CDC advisers recommend seasonal use of Pfizer RSV shot

Medical student insurance fails on mental health care coverage

Senate HELP committee spars over health care workforce policies

Medical student insurance fails on mental health care coverage

focus

explore

leisure time

focus